Bitcoin Forum
December 05, 2022, 01:11:52 AM *
News: Latest Bitcoin Core release: 23.0 [Torrent]
 
   Home   Help Search Login Register More  
Warning: One or more bitcointalk.org users have reported that they strongly believe that the creator of this topic is a scammer. (Login to see the detailed trust ratings.) While the bitcointalk.org administration does not verify such claims, you should proceed with extreme caution.
Pages: « 1 2 3 4 5 6 [7] 8 9 10 11 12 »  All
  Print  
Author Topic: [ANN][INNBC]INNOVATIVE BIORESEARCH 💚 Funding AIDS cure research*get JDM cars 🚗  (Read 17770 times)
INNOVATIVE BIORESEARCH
Newbie
*
Offline Offline

Activity: 340
Merit: 0


View Profile WWW
May 24, 2018, 07:45:32 PM
 #121

ICO listed on ICO timer, biggest japanese ICO listing site.

https://ico-timer.com/innovativebioresearchcoin-innbc/
1670202712
Hero Member
*
Offline Offline

Posts: 1670202712

View Profile Personal Message (Offline)

Ignore
1670202712
Reply with quote  #2

1670202712
Report to moderator
1670202712
Hero Member
*
Offline Offline

Posts: 1670202712

View Profile Personal Message (Offline)

Ignore
1670202712
Reply with quote  #2

1670202712
Report to moderator
1670202712
Hero Member
*
Offline Offline

Posts: 1670202712

View Profile Personal Message (Offline)

Ignore
1670202712
Reply with quote  #2

1670202712
Report to moderator
The forum was founded in 2009 by Satoshi and Sirius. It replaced a SourceForge forum.
Advertised sites are not endorsed by the Bitcoin Forum. They may be unsafe, untrustworthy, or illegal in your jurisdiction.
1670202712
Hero Member
*
Offline Offline

Posts: 1670202712

View Profile Personal Message (Offline)

Ignore
1670202712
Reply with quote  #2

1670202712
Report to moderator
1670202712
Hero Member
*
Offline Offline

Posts: 1670202712

View Profile Personal Message (Offline)

Ignore
1670202712
Reply with quote  #2

1670202712
Report to moderator
INNOVATIVE BIORESEARCH
Newbie
*
Offline Offline

Activity: 340
Merit: 0


View Profile WWW
May 25, 2018, 06:36:45 AM
 #122

Let me now if you have any issue with the Token sale.
INNOVATIVE BIORESEARCH
Newbie
*
Offline Offline

Activity: 340
Merit: 0


View Profile WWW
May 25, 2018, 01:29:42 PM
 #123

New youtube review of our ICO

https://www.youtube.com/watch?v=hwMn5WKgEQI
INNOVATIVE BIORESEARCH
Newbie
*
Offline Offline

Activity: 340
Merit: 0


View Profile WWW
May 25, 2018, 02:18:26 PM
 #124

Possible listing of our Token on Evercoin.
INNOVATIVE BIORESEARCH
Newbie
*
Offline Offline

Activity: 340
Merit: 0


View Profile WWW
May 25, 2018, 05:49:46 PM
 #125

New youtube ICO review

https://www.youtube.com/watch?v=7SnQuaMtMes
INNOVATIVE BIORESEARCH
Newbie
*
Offline Offline

Activity: 340
Merit: 0


View Profile WWW
May 27, 2018, 08:59:59 AM
 #126

Mr. Bitcoin ICO review

https://www.youtube.com/watch?v=poyLH8ZKFhU

Mr. Bitcoin knows his stuff Wink

INNOVATIVE BIORESEARCH
Newbie
*
Offline Offline

Activity: 340
Merit: 0


View Profile WWW
May 27, 2018, 11:00:07 AM
 #127

Nice compilation of Youtube reviews of our ICO; our project is getting great recognition from the cryptocommunity Wink

https://www.youtube.com/watch?v=b74vb5zjq7E
https://www.youtube.com/watch?v=I2KUAyxpQwM
https://www.youtube.com/watch?v=ktPXafMlLmE
https://www.youtube.com/watch?v=EeKpIVSsRkQ
https://www.youtube.com/watch?v=KGR36O_ibEM
https://www.youtube.com/watch?v=5KIJhzIcoSU
https://www.youtube.com/watch?v=P2rhFOidtyA
https://www.youtube.com/watch?v=N6oGd9o9Epg
https://www.youtube.com/watch?v=hwMn5WKgEQI
https://www.youtube.com/watch?v=7SnQuaMtMes
https://www.youtube.com/watch?v=poyLH8ZKFhU
Prosperityforall
Member
**
Offline Offline

Activity: 490
Merit: 14


View Profile
May 27, 2018, 05:07:12 PM
 #128

Wow, these are nice ICO reviews. Now I see that your company is credible one and what I like more is that you bring real value to people.
If you will be able to solve AID issue and find a solution, you will make a breakthrough
INNOVATIVE BIORESEARCH
Newbie
*
Offline Offline

Activity: 340
Merit: 0


View Profile WWW
May 27, 2018, 06:10:14 PM
 #129


Thanks. This project is based on our biomedical research, which is what makes it stand out from other ICOs that are not connected to any real business.
Freddy63
Member
**
Offline Offline

Activity: 434
Merit: 10

SESSIA


View Profile
May 27, 2018, 07:26:43 PM
 #130


Thanks. This project is based on our biomedical research, which is what makes it stand out from other ICOs that are not connected to any real business.
I've recently noticed your ICO. The point is that nobody before never invented something against AID and cancer or their inventions are useless.
What distinct you from numerous projects without any results. Why do you think that you will invent medicine against AID?

[ S E S S I A ] NEW GENERATION SOCIAL NETWORK
twitter    ◾ telegram     (❪  W H I T E P A P E R  ❫)
GET APP  ❱❱❱  ► Google Play   ► App Store
Koontas
Hero Member
*****
Offline Offline

Activity: 784
Merit: 502



View Profile
May 27, 2018, 07:47:25 PM
 #131

Let me now if you have any issue with the Token sale.
I tried to register but I do not receive any confirmation mail. Tried with gmail address and with a self hosted email service. Already checked the log files, but there is no email incoming.

Don't trust any exchange!
INNOVATIVE BIORESEARCH
Newbie
*
Offline Offline

Activity: 340
Merit: 0


View Profile WWW
May 27, 2018, 09:58:37 PM
Last edit: June 19, 2018, 11:37:48 AM by INNOVATIVE BIORESEARCH
 #132

Let me now if you have any issue with the Token sale.
I tried to register but I do not receive any confirmation mail. Tried with gmail address and with a self hosted email service. Already checked the log files, but there is no email incoming.

Hello,



From our FAQ, which you can find on the ICO page.


How can I buy your Tokens?



Participating in our Token sale is very easy. Step 1. You need to register with us. To register, just send an email to administrator@innovativebioresearch.com with the following information: your name, email address, the ETH address where you want to receive your INNBC Tokens, and the ETH/BTC address from which you will be sending funds. We only accept funds in ETH and BTC. Please provide this data before sending funds, otherwise if you pay in BTC we will have no idea what is the associated ETH wallet. Please also wait for an email confirmation after you register before sending funds. Step 2. Send funds to purchase your INNBC Tokens. We only accept payments in ETH/BTC. This is our ETH address: 0xB8EB02A17a3eB5cE4F8249553d8C17B406036AaD and this is our BTC address: 1HLMcK1MomKtkumcmzELx5eLR3qt1k4jAo. You will receive your INNBC Tokens shortly after purchasing. Step 3. To add your Tokens to Myetherwallet, select "add custom Token" and insert the following paramethers: Token Contract Address: 0x85558055812f19eB084B8bA327470e84Ad795b11, Token Symbol: INNBC, Decimals: 8.



Who distributes Tokens, and how quickly will I receive them after the end of the initial offer (Token Launch)?




INNBC Tokens are distributed to investors shortly after purchase.
INNOVATIVE BIORESEARCH
Newbie
*
Offline Offline

Activity: 340
Merit: 0


View Profile WWW
May 27, 2018, 10:22:12 PM
 #133

ICO now also listed on ICObuffer

https://icobuffer.com/projects/innovative_bioresearch
INNOVATIVE BIORESEARCH
Newbie
*
Offline Offline

Activity: 340
Merit: 0


View Profile WWW
May 27, 2018, 10:50:18 PM
Last edit: May 28, 2018, 10:03:41 AM by INNOVATIVE BIORESEARCH
 #134

I've recently noticed your ICO. The point is that nobody before never invented something against AID and cancer or their inventions are useless.
What distinct you from numerous projects without any results. Why do you think that you will invent medicine against AID?

Actually, we have conceived a very innovative cell-based therapy for HIV that uses the SupT1 cell line as a decoy target for the HIV virus. Our approach is unique as no other therapy tried to use a permissive T cell-line as a decoy target for the HIV virus. Furthermore, this is a cell-based approach, which is something completely different than traditional drug based approaches that failed to produce an AIDS cure. So we are not in need of inventing a new solution, we just need to further develop the HIV therapy we have already conceived, completing preclinical animal research and move to human trials. I'll post some information from our website regarding our novel AIDS therapy solution.


An Overview of SupT1 Cell Infusion Therapy, our Novel Cell-Based Therapy Solution for HIV


HIV infection usually leads to a progressive decline in number and functionality of CD4+ T lymphocytes, resulting in AIDS development. As explained in Jonathan Fior’s papers [1–3], the HIV virus has a higher tropism for SupT1 cells than for primary CD4+ T cells. Several hypotheses have been proposed as an explanation, most notably the higher surface expression of CD4 and CXCR4 receptors in SupT1 cells. In addition, in vitro studies of HIV evolution show that persistent growth in the SupT1 cell line results in a less cytopathic virus with a reduced capacity for syncytium formation, a higher sensitivity to neutralization, improved replication in SupT1 cells and impaired infection of primary CD4+ T cells [4–6]. Accordingly, Jonathan Fior proposed the infusion of irradiated SupT1 cells as a cell-based HIV therapy to exploit the therapeutic potential of these phenomena [1–3]. The rationale behind this approach is that moving infection toward the inoculated cells should prevent infection and depletion of the patient’s own CD4+ T cells and, therefore, AIDS. In such a strategy, SupT1 cells would act as a “decoy target” for the HIV virus to prevent CD4+ T cell depletion as well as to render the virus less cytopathic. As previously mentioned, in vitro studies of HIV evolution show that prolonged replication in SupT1 cells renders the virus less cytopathic and more sensitive to neutralization. Accordingly, replication of the virus in the inoculated SupT1 cells should also have a vaccination effect; that is, the therapy should also induce the virus to become progressively less aggressive and harmful for the patient. The use of SupT1 cells as a decoy target for HIV has been investigated in vitro and in vivo, with interesting results [1,3]. In vitro data showed that, when primary CD4+ T cells are infected with HIV in the presence of SupT1 cells, the preferential infection of SupT1 cells can spare primary CD4+ T cells from infection and depletion. In vivo data in humanized mice showed that significantly lower viral replication (~10-fold) and potentially preserved CD4+ T cell frequency at Week 1 was scored in animals treated with SupT1 cell infusion. Of note, one animal exhibited a sustained decrease in HIV replication and CD4+ T cell depletion (no virus detected anymore at Weeks 3 and 4), a result that may hold the key to future HIV treatments. Given the urgent and global need for a cost effective cure for HIV, we believe that the millions of people infected by this terrible disease deserve highly innovative HIV cure research strategies, such as SupT1 cell infusion therapy.

In summary, these are some of the potential therapeutic benefits of this cell-based treatment that go beyond what can be achievable with traditional antiretroviral therapy (cART):

1)The vaccination effect. As previously mentioned, SupT1 cells have been shown to have a very powerful vaccination effect in vitro [4–6]. In this regard, in vitro studies of HIV evolution showed that upon prolonged replication in SupT1 cells, the X4 HIV-1 LAI virus evolves toward a less virulent phenotype with a reduced capacity for syncytium formation, thus losing the main cytopathic feature characterizing X4 strains, and most notably the virus adaptation to replicate in SupT1 cells results in gradually losing the ability to replicate in primary CD4+ T cells [4]. In addition, the variation to neutralization sensitivity after viral growth in tumor T cell lines has also been examined. Interestingly, one study reported that primary isolates that were initially resistant to neutralization acquired sensitivity to neutralization after continuous growth in tumor T cell lines, and that the sensitivity to neutralization progressively increased during the days of culturing [5]. Specifically, it was shown that after 14 days in continuous culture, 100 micrograms/mL of rsCD4 (recombinant soluble CD4) were needed to neutralize 1 TCID of primary isolate, while only 0.3 micrograms/mL of rsCD4 were needed to neutralize 1 TCID of the virus after 75 days in continuous culture. This means that there was a 300 fold increase in virus sensitivity to neutralization after prolonged replication in a tumor T cell line, which is really something remarkable. All these phenomena could therefore harbor a significant therapeutic potential that could be exploited with SupT1 cell infusion therapy to induce HIV infection to evolve into a more tractable state for therapy.

2)Potentially no organ toxicity; cART is a drug based treatment and as such is associated with organ toxicity because the drugs are metabolized by various organs. By contrast, SupT1 cell infusion is a cell-based treatment and there is no chemical substance injected into the body that needs to be metabolized, which could significantly improve the quality of the patient's life.

3)Be effective in patients in a terminal state of disease that developed drug resistant and very aggressive HIV strains. When a patient is treated with cART, the virus fights back because it strives to survive, which can result in the development of very aggressive and drug resistant HIV strains, especially in the terminal stage of the disease and in such cases cART becomes ineffective. By contrast, SupT1 cell infusion therapy provides the virus with a permissive cell-line in which it can preferentially replicate, so that a peaceful coexistence between virus and host becomes possible, which could dramatically improve the patient's health as the virus infection progressively moves toward the inoculated SupT1 cells and the virus becomes increasingly less pathogenic for its host.

4)Possible association of the treatment with novel molecular compounds such as a Vif-inhibitor to act on HIV reservoirs. The HIV-1 Vif protein is essential for viral replication in primary CD4+ T cells but not in SupT1 cells [1]. Accordingly, pharmacologic inhibition of Vif could be combined with SupT1 cell infusion to further restrict viral replication to the inoculated SupT1 cells. Considering that APOBEC3G is expressed by different cell types, such as neuronal cells, astrocytes, and macrophages [2], pharmacologic inhibition of Vif may also have the benefit of acting on HIV reservoirs in the brain and other body areas. There are several molecules with promising anti-Vif activity currently being tested [2]. Similarly, other HIV-1 accessory proteins that are not essential for replication in SupT1 cells (e.g., Vpr, Vpu, and Nef [3]) may also be the target of pharmacologic inhibition. It is important to point out that these drugs would not affect virus replication in the inoculated SupT1 cells, and therefore in combination with SupT1 cell infusion therapy, there should not be development of drug resistance normally associated with drug based treatments.

​5)A cost effective AIDS cure solution. Our mission is to provide a cost effective cure solution for AIDS. In contrast with traditional cell-based and gene-based therapies that make use of modified autologous cells and are therefore very expensive and often unpractical for a large scale application, using a standardized T cell line such as the SupT1 cell line should significantly reduce the treatment costs associated with SupT1 cell infusion therapy, allowing access to the therapy where access to traditional HIV therapies is restricted by economic and social limitations. The social and economical impacts of a low cost HIV cure solution would be enormous.

Below some considerations with regard to potential issues:

1)Safety. We take this issue very seriously and are committed to performing very rigorous preclinical research to ensure there is enough data on safety to obtain approval from regulatory agencies for human experimentation. In this regard, injection of irradiated tumor cells as a therapy is already performed in cancer vaccination. In such cases, irradiating the cells prior to inoculation has been shown to ensure treatment safety both in animal and clinical studies [7]. We used the same protocol used in cancer vaccination studies (i.e., 30 Gy of radiation dose for the cells), which resulted in safe in vivo inoculation in our animal study as well [3]. Specifically, all animals successfully survived the treatment and presence of SupT1 cells was almost undetectable at late time points, which means that irradiating the cells prior to inoculation efficiently prevented SupT1 cell replication. Furthermore, we infused high doses of cells (40 million SupT1 cells were infused weekly), which in a highly immunodeficient mouse strain would rapidly lead to animal death in case of tumor development. Therefore, based on the clinical data we already have from cancer vaccination studies, and from the results of our first animal study, we believe that meeting the safety standards required for human trials is something feasible.

2)Rejection issues. Tumors can develop because tumor cells are able to evade immune recognition. For example, SupT1 cells do not express HLA-DR, which is an antigen highly associated with immune recognition [8]. Accordingly, given the tumoral nature of SupT1 cells, they should be significantly less immunogenic than normal cells and as such should survive in the patient long enough to provide a therapeutic effect. However, it is possible that the HIV virus will eradicate the cells faster and more efficiently than the immune system itself in any case.

References

1. Fior J. An initial in vitro investigation into the potential therapeutic use of SupT1 cells to prevent AIDS in HIV-seropositive individuals. PLoS ONE. 2012;7:13.

2. Fior J. Is a pacific coexistence between virus and host the unexploited path that may lead to an HIV functional cure? Viruses. 2013;5:753–757.

3. Fior, J. SupT1 Cell Infusion as a Possible Cell-Based Therapy for HIV: Results from a Pilot Study in Hu-PBMC BRGS Mice. Vaccines. 2016, 4:13.

4. Das, A.T.; Land, A.; Braakman, I.; Klaver, B.; Berkhout, B. HIV-1 evolves into a nonsyncytiuminducing virus upon prolonged culture in vitro. Virology. 1999, 263:55–69.

5. Turner, S.; Tizard, R.; DeMarinis, J.; Pepinsky, R.B.; Zullo, J.; Schooley, R.; Fisher, R. Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120. Proc. Natl. Acad. Sci. USA. 1992, 89:1335–1339.

6. Moore, J.P.; Burkly, L.C.; Connor, R.I.; Cao, Y.; Tizard, R.; Ho, D.D.; Fisher, R.A. Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4. AIDS Res. Hum. Retroviruses. 1993, 9:529–539.

7. Salgia R, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. 2003, 21:624–630.

8. Dufresne I, et al. Targeting lymph nodes with liposomes bearing anti-HLA-DR Fab′ fragments. Biochim Biophys Acta. 1999, 1421:284-94.









INNOVATIVE BIORESEARCH
Newbie
*
Offline Offline

Activity: 340
Merit: 0


View Profile WWW
May 28, 2018, 01:03:20 PM
Last edit: May 28, 2018, 01:27:16 PM by INNOVATIVE BIORESEARCH
 #135

I've recently noticed your ICO. The point is that nobody before never invented something against AID and cancer or their inventions are useless.
What distinct you from numerous projects without any results. Why do you think that you will invent medicine against AID?

Now, in the previous post I gave you a technical explanation about why our treatment is novel and is exploring approaches never tested before. However, there is also an economic explanation why there is such an extreme lack of innovation in this field.

There is the huge business of the pharmaceutical corporations selling expensive HIV drug, which aim to make as much profit as possible off of AIDS. These companies would never support the development of a low cost AIDS cure because it would put an end to their huge profits. This is precisely why we need a project such as this one in our society.

There were 36.7million people infected by HIV globally in 2016, 17.5million of which were left untreated, according to UNAIDS. Our mission is to develop a low cost cell-based therapy solution for HIV to allow access to the treatment for those individuals who are normally left untreated due to social and/or economic limitations.
INNOVATIVE BIORESEARCH
Newbie
*
Offline Offline

Activity: 340
Merit: 0


View Profile WWW
May 28, 2018, 01:23:54 PM
 #136

New youtube review of our ICO

https://www.youtube.com/watch?v=qAQdVaJlExg
MS_Sol
Newbie
*
Offline Offline

Activity: 106
Merit: 0


View Profile
May 28, 2018, 01:27:32 PM
 #137

New youtube review of our ICO

https://www.youtube.com/watch?v=qAQdVaJlExg
If your research will be successful, that is fantastic... good Luck
INNOVATIVE BIORESEARCH
Newbie
*
Offline Offline

Activity: 340
Merit: 0


View Profile WWW
May 28, 2018, 02:23:26 PM
Last edit: May 28, 2018, 05:27:15 PM by INNOVATIVE BIORESEARCH
 #138

New youtube review of our ICO

https://www.youtube.com/watch?v=qAQdVaJlExg
If your research will be successful, that is fantastic... good Luck

Thanks. As the Token utility is directly related to the research, this should also make the Token skyrocket in value. Unlike other Tokens on the market for which the price is just the result of whatever the market feels, the INNBC Token is connected to a real business and as such is backed by real assets.
INNOVATIVE BIORESEARCH
Newbie
*
Offline Offline

Activity: 340
Merit: 0


View Profile WWW
May 28, 2018, 10:07:13 PM
 #139

Guess what?  New youtube ICO review Wink

https://www.youtube.com/watch?v=8ETT4wy2HwI

Love these reviews.
INNOVATIVE BIORESEARCH
Newbie
*
Offline Offline

Activity: 340
Merit: 0


View Profile WWW
May 28, 2018, 10:33:46 PM
 #140

New very nice article about our ICO

https://golos.io/bitcoin/@sofasharikova/innovative-bioresearch-platform-for-support-of-researches-in-the-sphere-searching-ways-treatment-aids-and-cancer
Pages: « 1 2 3 4 5 6 [7] 8 9 10 11 12 »  All
  Print  
 
Jump to:  

Powered by MySQL Powered by PHP Powered by SMF 1.1.19 | SMF © 2006-2009, Simple Machines Valid XHTML 1.0! Valid CSS!